Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$25.06 - $34.09 $13,632 - $18,544
-544 Reduced 6.98%
7,255 $205,000
Q3 2022

Nov 14, 2022

SELL
$26.42 - $47.12 $135,878 - $242,338
-5,143 Reduced 39.74%
7,799 $206,000
Q2 2022

Aug 12, 2022

SELL
$41.26 - $51.35 $19,969 - $24,853
-484 Reduced 3.6%
12,942 $575,000
Q1 2022

May 16, 2022

BUY
$44.58 - $52.6 $64,328 - $75,901
1,443 Added 12.04%
13,426 $664,000
Q4 2021

Feb 14, 2022

BUY
$45.82 - $56.9 $9,668 - $12,005
211 Added 1.79%
11,983 $610,000
Q3 2021

Nov 15, 2021

BUY
$43.79 - $55.78 $229,590 - $292,454
5,243 Added 80.3%
11,772 $656,000
Q2 2020

Aug 14, 2020

BUY
$43.24 - $55.02 $5,534 - $7,042
128 Added 2.0%
6,529 $313,000
Q1 2020

May 15, 2020

SELL
$34.37 - $60.07 $127,650 - $223,099
-3,714 Reduced 36.72%
6,401 $294,000
Q4 2019

Feb 14, 2020

BUY
$54.32 - $64.31 $185,448 - $219,554
3,414 Added 50.95%
10,115 $607,000
Q1 2019

May 14, 2019

BUY
$38.66 - $51.82 $54,162 - $72,599
1,401 Added 26.43%
6,701 $0
Q2 2018

Aug 14, 2018

BUY
$51.25 - $76.62 $271,625 - $406,086
5,300 New
5,300 $0

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $6.51M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.